Program
trastuzumab rezetecan
Also written as “SHR-A1811”, “SHR-A1811 for Injection” and “SHR-A1811 Injection”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Colorectal Neoplasms · Ovarian Neoplasms, led by Jiangsu HengRui Medicine.
Drug pageTrastuzumab rezetecan: every studyAll 103 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 3632 open or running | phase 3since Jun 15, 2022 | Jun 18, 2020 | Dec 2026phase 2 · NCT06840002 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 19 earlier studies, Jun 18, 2020 to May 21, 2024.
- Jul 21, 2022Named trastuzumab rezetecanINNProposed as its International Nonproprietary Name in WHO's List 127
- Sep 9, 2024Phase 2 study in Untreated Early-stage or Locally Advanced Breast CancerNCT06592625 · 60 planned · China
- Nov 25, 2024Phase 1 study in Advanced Breast CancerNCT06710990 · 17 enrolled · China
- Feb 10, 2025Phase 3 study in Ovarian NeoplasmsNCT06828354 · 300 planned · China
- Feb 17, 20252 phase 2 studiesNCT06840002, NCT06859775
- Jun 26, 2025Phase 2 study in RecurrenceNCT07051486 · 60 planned · China
- Jul 31, 2025Phase 2 study in Stomach NeoplasmsNCT07110571 · 200 planned · China
- Aug 1, 20252 phase 3 studiesNCT07111832, NCT07118527
- Aug 17, 2025Phase 2 study in Solid TumorNCT07140393 · 120 planned · China
- Sep 22, 2025Phase 3 study in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · 740 enrolled · China
- Nov 27, 2025Phase 1 study in Solid TumorNCT07275242 · 107 planned · China
- Mar 19, 2026Phase 2 study in Unresectable Locally Recurrent Breast CancerNCT07497386 · 150 planned · China
- Jun 23, 20262 phase 3 studiesNCT07676162, NCT07679360
- Aug 28, 2026Phase 2 study in Advanced Colorectal Cancer Expressing HER2NCT07796763 · 48 planned · United States
- Oct 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07896005 · 436 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Ovarian NeoplasmsNCT06840002
- Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT05482568
- Dec 31, 2026Primary completion: phase 2 study in HER2 Expression / Amplification in Patients With Biliary Tract CancerNCT06413745
- Dec 31, 2026Primary completion: phase 3 study in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07896005Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Feb 2031 | 436 |
| NCT07796763Advanced Colorectal Cancer Expressing HER2 · United States | 2 | Not yet recruiting | May 1, 2028 | 48 |
| NCT07679360Triple Negative Breast Neoplasms · China | 3 | Recruiting | Dec 2030 | 1,000 |
| NCT07676162Advanced Colorectal Cancer · China | 3 | Recruiting | Sep 2029 | 300 |
| NCT07497386Unresectable Locally Recurrent Breast Cancer · China | 2 | Recruiting | Jun 2028 | 150 |
| NCT07275242Solid Tumor · China | 1 | Recruiting | Jun 2027 | 107 |
| NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Dec 2027 | 740 |
| NCT07140393Solid Tumor · China | 2 | Recruiting | Oct 2027 | 120 |
| NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Oct 2030 | 600 |
| NCT07111832Triple Negative Breast Neoplasms · China | 3 | Recruiting | Mar 2028 | 400 |
| NCT07110571Stomach Neoplasms · China | 2 | Recruiting | Aug 2026 | 200 |
| NCT07051486Recurrence · China | 2 | Recruiting | Feb 2026 | 60 |
| NCT06859775Recurrence · China | 2 | Recruiting | Oct 2026 | 100 |
| NCT06840002Ovarian Neoplasms · China | 2 | Recruiting | Dec 2026 | 150 |
| NCT06828354Ovarian Neoplasms · China | 3 | Recruiting | May 2027 | 300 |
| NCT06710990Advanced Breast Cancer · China | 1 | Completed | Oct 15, 2025 | 17 |
| NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China | 2 | Not yet recruiting | Feb 28, 2026 | 60 |
| NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations · China | 3 | Recruiting | Feb 2026 | 300 |
| NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer · China | 2 | Active, not recruiting | Dec 31, 2026 | 59 |
| NCT06199973Advanced Colorectal Cancer · China | 3 | Active, not recruiting | Apr 2026 | 130 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Oct 31, 2026 | 350 |
| NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy · China | 3 | Active, not recruiting | Apr 2030 | 1,615 |
| NCT06123494HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Jun 30, 2027 | 360 |
| NCT06057610Breast Neoplasms · China | 3 | Active, not recruiting | Jul 15, 2026 | 868 |
| NCT05896020Gynaecological Malignancies · China | 2 | Recruiting | Jun 15, 2026 | 225 |
| NCT05845138Breast Neoplasms · China | 2 | Recruiting | Dec 31, 2024 | 116 |
| NCT05814354Breast Neoplasms · China | 3 | Active, not recruiting | Mar 20, 2026 | 551 |
| NCT05792410Breast Neoplasms | 2 | Not yet recruiting | Feb 27, 2024 | 300 |
| NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Dec 2027 | 258 |
| NCT05482568Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Dec 2026 | 324 |
| NCT05424835HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane · China | 3 | Active, not recruiting | Dec 31, 2026 | 381 |
| NCT05349409Advanced Solid Tumors · China | 2 | By invitation | Nov 30, 2024 | 212 |
| NCT05353361Breast Neoplasms · China | 2 | UNKNOWN | Dec 31, 2025 | 402 |
| NCT04818333Advanced Non-small Cell Lung Cancer · China | 2 | Active, not recruiting | Jun 2025 | 157 |
| NCT04513223Stomach Neoplasms · China | 1 | Completed | Mar 28, 2025 | 101 |
| NCT04446260Advanced Solid Tumors · United States, Australia, China and more | 1 | Completed | Jun 4, 2025 | 396 |
How it is read
Names in the registry
- “SHR-A1811”, 17 entries
- “SHR-A1811 for Injection”, 4 entries
- “SHR-A1811 Injection”, 3 entries
- “Trastuzumab Rezetecan for Injection”, 2 entries
- “SHR-A1811 and capecitabine”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 12 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Stomach Neoplasms, 4 studies
- Colorectal Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.